We need a better debate about US pharma patents
Opinion: Popular attacks on America’s life sciences patent system are highly misleading
Opinion: Popular attacks on America’s life sciences patent system are highly misleading
Surprise intervention of US government has not helped the mRNA company
Patentees may be able to avoid the loss of exclusivity created by another recent top court decision
06 December 2022
Imago BioSciences buyout is intended to diversify the company’s revenue streams
28 November 2022
Saturday Opinion: In its petition for certiorari, Amgen painted a picture of a Federal Circuit run amok. However, the dichotomy presented by Amgen in its petition for certiorari is a false one
26 November 2022
The company’s latest win means that its second highest selling drug will not face US competition for a decade
22 November 2022
New policy statement likely to target pay-for-delay deals and sham litigation
18 November 2022
The second instalment of the joint IAM-Docket Navigator US litigation report focuses on the most contentious technology centres in 2022’s third quarter
18 November 2022
Selling revenue streams is an increasingly important way of monetising pharma innovations
16 November 2022
While WTO member states have expressed general sympathy for the goal to provide broad access to vaccine technology during the pandemic, Germany continues to favour patent protection over compulsory licensing.
16 November 2022
District Court decision could mean plaintiffs have more power to control speed and scope of US litigation
14 November 2022
Head of Singapore-based startup reflects on the importance of patents in ensuring its products are proprietary and unique
10 November 2022
Unlock unlimited access to all IAM content